NO983474L - Ekspresjon av gruppe B Neisseria meningitidis ytre membran (MB3) protein fra gjµr og vaksiner - Google Patents

Ekspresjon av gruppe B Neisseria meningitidis ytre membran (MB3) protein fra gjµr og vaksiner

Info

Publication number
NO983474L
NO983474L NO983474A NO983474A NO983474L NO 983474 L NO983474 L NO 983474L NO 983474 A NO983474 A NO 983474A NO 983474 A NO983474 A NO 983474A NO 983474 L NO983474 L NO 983474L
Authority
NO
Norway
Prior art keywords
group
protein
yeast
outer membrane
meningococcal
Prior art date
Application number
NO983474A
Other languages
English (en)
Other versions
NO983474D0 (no
Inventor
Joseph Y Tai
Michail Donets
Ming-Der Wang
Shu-Mei Liang
Marvellen Palvino-Bodnar
Conceicao A S A Minetti
Francis Michon
Original Assignee
North American Vaccine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North American Vaccine Inc filed Critical North American Vaccine Inc
Publication of NO983474D0 publication Critical patent/NO983474D0/no
Publication of NO983474L publication Critical patent/NO983474L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Det er beskrevet en fremgangsmåte for oppnåelse av ytre membranprotein meningococcal gruppe B porin proteiner, spesielt MB3, og fusjonsproteiner derav. Det er spesielt beskrevet en fremgangsmåte for uttrykking av ytre membranprotein meningococcal gruppe B porin proteiner i gjær. Det er også beskrevet en fremgangsmåte for ekspresjon i høyt nivå av ovennevnte proteiner hvori raten til proteinekspresjon blir forsterket ved substituering av en nukleotidsekvens til 5' regionen av genet kodende for nevnte protein hvori sekvensen er blitt optimalisert for gjærkodonbruk. Det er videre beskrevet en vaksine omfattende gruppe A meningococcal polysakkarid (GAMP), gruppe B meningococcal polysakkarid (GBMP) og gruppe C meningococcal polysakkarid (GCMP) antigener, sammen med en farmasøytisk akseptabel bærer. Det er også beskrevet en fremgangsmåte for indusering av en immunrespons i et pattedyr omfattende administrering av ovennevnte vaksine til pattedyr i en mengde som er tilstrekkelig for å indusere en immunrespons.
NO983474A 1996-02-01 1998-07-28 Ekspresjon av gruppe B Neisseria meningitidis ytre membran (MB3) protein fra gjµr og vaksiner NO983474L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1097296P 1996-02-01 1996-02-01
US2044096P 1996-06-13 1996-06-13
PCT/US1997/001687 WO1997028273A1 (en) 1996-02-01 1997-01-31 Expression of group b neisseria meningitidis outer membrane (mb3) protein from yeast and vaccines

Publications (2)

Publication Number Publication Date
NO983474D0 NO983474D0 (no) 1998-07-28
NO983474L true NO983474L (no) 1998-09-30

Family

ID=26681820

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983474A NO983474L (no) 1996-02-01 1998-07-28 Ekspresjon av gruppe B Neisseria meningitidis ytre membran (MB3) protein fra gjµr og vaksiner

Country Status (9)

Country Link
EP (1) EP0877816A1 (no)
JP (1) JP2001508758A (no)
KR (1) KR19990082265A (no)
AU (1) AU2115897A (no)
HU (1) HUP9901039A2 (no)
IL (1) IL125420A0 (no)
NO (1) NO983474L (no)
PL (1) PL328096A1 (no)
WO (1) WO1997028273A1 (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2297072A1 (en) 1997-07-17 1999-01-28 Baxter Healthcare S.A. Immunogenic conjugates comprising a group b meningococcal porin and an h. influenzae polysaccharide
EP2261338A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
DE69941406D1 (de) * 1998-07-06 2009-10-22 Tosoh Corp IL-6 Rezeptor IL-6-gekoppeltes Fusionsprotein
JP4524816B2 (ja) * 1998-07-06 2010-08-18 東ソー株式会社 Ｉｌ−６レセプター・ｉｌ−６直結融合蛋白質
GB9818004D0 (en) * 1998-08-18 1998-10-14 Smithkline Beecham Biolog Novel compounds
WO2000066741A2 (en) 1999-04-30 2000-11-09 Chiron S.P.A. Conserved neisserial antigens
NZ515322A (en) 1999-05-13 2004-03-26 Wyeth Corp Adjuvant combination formulations
NZ515935A (en) * 1999-05-19 2004-01-30 Chiron S Combination Neisserial compositions and vaccines for the prevention of infections due to Neisseria bacteria such as meningococcal meningitis
EP1069133A1 (en) 1999-07-13 2001-01-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Neisseria meningitidis compounds and anti-infection applications thereof
BR0015961A (pt) * 1999-11-29 2003-06-10 Chiron Spa Antìgeno de neisseria de 85kda
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
PT2289545T (pt) 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
NZ521531A (en) 2000-02-28 2005-12-23 Chiron S Heterologous expression of neisserial proteins
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
EP2172213B1 (en) 2003-01-30 2013-04-03 Novartis AG Injectable vaccines against multiple meningococcal serogroups
JP2006262846A (ja) * 2005-03-25 2006-10-05 Niigata Bio Research Park Kk 酵母による２−デオキシ−シロ−イノソースの合成および精製する方法並びに得られた２−デオキシ−シロ−イノソース
KR100919704B1 (ko) * 2007-09-12 2009-10-06 한국생명공학연구원 효모에서 재조합단백질을 고효율로 분비발현시키는 방법
JP2011116658A (ja) * 2008-03-13 2011-06-16 Chemo-Sero-Therapeutic Research Inst 豚萎縮性鼻炎用薬剤の製造方法
US9974848B2 (en) 2013-11-14 2018-05-22 Duke University Tetanus toxoid and CCL3 improve DC vaccines
CN106146679B (zh) * 2015-04-23 2019-02-01 中国医学科学院医学生物学研究所 一种纯化细菌荚膜多糖的方法
PT3294762T (pt) 2015-05-11 2022-03-21 Impossible Foods Inc Constructos de expressão e métodos de modificar geneticamente levedura metilotrófica
CA3010288A1 (en) * 2015-12-30 2017-07-06 Dsm Ip Assets B.V. Partial enzymatic hydrolysis of triacylglycerols
AU2020257270B2 (en) 2019-04-17 2026-01-15 Impossible Foods Inc. Materials and methods for protein production
WO2025065137A1 (zh) * 2023-09-25 2025-04-03 万华化学集团股份有限公司 一种高密度发酵生产单细胞蛋白的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5268273A (en) * 1990-12-14 1993-12-07 Phillips Petroleum Company Pichia pastoris acid phosphatase gene, gene regions, signal sequence and expression vectors comprising same
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis

Also Published As

Publication number Publication date
JP2001508758A (ja) 2001-07-03
EP0877816A1 (en) 1998-11-18
IL125420A0 (en) 1999-03-12
PL328096A1 (en) 1999-01-04
AU2115897A (en) 1997-08-22
WO1997028273A1 (en) 1997-08-07
HUP9901039A2 (hu) 1999-07-28
NO983474D0 (no) 1998-07-28
KR19990082265A (ko) 1999-11-25

Similar Documents

Publication Publication Date Title
NO983474L (no) Ekspresjon av gruppe B Neisseria meningitidis ytre membran (MB3) protein fra gjµr og vaksiner
Matsuo et al. Establishment of a foreign antigen secretion system in mycobacteria
Ellis Vaccines: New approaches to immunological problems
JP3633933B2 (ja) 弱毒化細菌における組換え融合タンパク質の発現
JP4827196B2 (ja) 髄膜炎菌類タンパク質ｎｍｂ１８７０のドメインおよびエピトープ
EA012037B1 (ru) Поливалентные вакцины, содержащие рекомбинантные вирусные векторы
CA1338705C (en) Vaccines obtained from antigenic gene products of recombinant genes
JPH03502687A (ja) レスピラトリイ・シンシチアル・ウイルス：ワクチンおよび診断法
GB9224584D0 (en) Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
US20150071963A1 (en) Chimeric poly peptides and the therapeutic use thereof against a flaviviridae infection
JP2002507396A5 (no)
US20100255033A1 (en) Non-toxic double mutant forms of pertussis toxin as adjuvants
AU5948490A (en) Recombinant poxvirus and streptococcal m protein vaccine
Taubman et al. Diepitopic construct of functionally and epitopically complementary peptides enhances immunogenicity, reactivity with glucosyltransferase, and protection from dental caries
WO2022003119A1 (en) Cross-reactive coronavirus vaccine
ES2236718T3 (es) Proteina portadora de efecto adyuvante, complejo inmunogenico que la contiene, su procedimiento de preparacion, secuencia nucleotidica y vacuna.
Guillén et al. Expression in Escherichia coli of the lpdA gene, protein sequence analysis and immunological characterization of the P64k protein from Neisseria meningitidis
JPH02163088A (ja) 緑膿菌のリポタンパク質ｉ
JP2011103893A (ja) 組換えインフルエンザ菌アドヘシンタンパク質
JPH05213995A (ja) Ｂ型肝炎ウイルスコア抗原のアミノ酸残基配列
US6309648B1 (en) Protective epitopes of adenyl cyclase-haemolysin (AC-Hly), their application to the treatment or to the prevention of bordetella infections
JPS6117523A (ja) 淋疾のための広域スペクトルワクチン
AU751646B2 (en) Hepatitis B virus polypeptides
Chen et al. A nontoxic Pseudomonas exotoxin A induces active immunity and passive protective antibody against Pseudomonas exotoxin A intoxication
Dorner et al. Bacterial toxin vaccines